Table 1 Characteristics of the study populations

n

55

23

Years of age [mean ± SD]

46.89 ± 19.3

43.1 ± 17.4

Females [n (%)]

21 (38.2%)

14 (60.9%)

Leukocytes/µl blood

[median (IQR)]

7200 (3260)

6980 (2370)

% lymphocytes in blood

[median (IQR)]

26.0 (11.1)

33.1 (5.4)

Neutrophil/lymphocyte ratio

[median (IQR)]

2.42 (1.47)

1.73 (0.48)

Days between 1st and 2nd

blood sampling, [mean ± SD]

13.8 ± 2.1

(n = 36)

14.0 ± 1.0

(n = 15)

Clinical characteristics PFP

Days since onset of symptoms

[mean ± SD]

2.6 ± 2.1

n.a

House–Brackmann grading (1–6)

[median (IQR)]^#

3.5 (1.5)

n.a

PFP side

Left

Right

Bilateral

32 (58.2%)

21 (38.2%)

2 (3.6%)

n.a

n.a

n.a

Lumbar puncture^§

(n = 47)

n.a

Normal cell counts (0–4 cells/µl)

Borderline (5 cells/µl)

Pleocytosis (> 5 cells/µl)*

35 (74.5%)

4 (8.5%)

8 (17.0%)

n.a

n.a

n.a

PFP-treatment [n]^$

52

n.a

Steroids

32

Anti-bacterial^b

1

Steroids/anti-viral^a

2

Anti-viral^a/anti-bacterial^b

7

Steroids/anti-viral^a/anti-bacterial^b

8

Immunoglobulins

2